Showing results (51-60 of 366) with videos related to

Sort By:
Pageof 37
Frontiers in Oncology|April 18, 2022
Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case ReportOriol Mirallas, Marc Bosch-Schips, Nuria Pardo, et al.
Cancer Treatment Reviews|April 21, 2017
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacyTony S K Mok, Lucio Crino, Enriqueta Felip, et al.
Advances in Therapy|October 20, 2025
A Time and Motion Study Comparing Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab in Combination with Chemotherapy for the Treatment of Metastatic Non-small Cell Lung CancerErwin De Cock, Sabine Oskar, Cecilia Lourdudoss, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 14, 2023
Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncologyAna Fernandez Montes, Elena Elez, Juan de la Haba-Rodriguez, et al.
Targeted Oncology|May 19, 2021
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 CohortBenjamin Tan, Adnan Khattak, Enriqueta Felip, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|March 28, 2025
Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genesHéctor Carlos García-Díaz, María Larrosa-Garcia, Javier Gómez-Alonso, et al.
Plos One|March 17, 2015
Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)Susana Cedrés, Santiago Ponce-Aix, Jon Zugazagoitia, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|June 28, 2025
Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genesHéctor Carlos García-Díaz, María Larrosa-Garcia, Javier Gómez-Alonso, et al.
Lung Cancer (Amsterdam, Netherlands)|February 24, 2009
Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinibSusana Cedrés, Aleix Prat, Pablo Martínez, et al.
Journal for Immunotherapy of Cancer|November 28, 2025
Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysisPablo Jimenez-Labaig, Oriol Mirallas, Ana Isabel Martin-Quesada, et al.
Pageof 37